03/09/23 4:05 PMNasdaq : ALGS earningslow floatAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress andRHEA-AIneutral
02/28/23 4:05 PMNasdaq : ALGS earningslow floatAligos Therapeutics to Announce Fourth Quarter Results March 9, 2023 Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nonalcoholic steatohepatitis (NASH) and viralRHEA-AIneutral
02/16/23 8:00 AMNasdaq : ALGS low floatAligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is deliveringRHEA-AIneutral
02/14/23 8:00 AMNasdaq : ALGS conferenceslow floatAligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliverRHEA-AIneutral
02/10/23 7:00 AMNasdaq : ALGS conferenceslow floatAligos Therapeutics to Present at the SVB Securities Global Biopharma ConferenceAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that Lawrence M. Blatt, Ph.D.,RHEA-AIneutral
02/08/23 4:05 PMNasdaq : ALGS covid-19low floatAligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024– Pipeline reprioritization emphasizes NASH and COVID-19 assets, ALG-055009 and ALG-097558, plus key ongoing collaborations, including the Merck & Co. (MSD) programs in NASH – – Overall workforce reduction (attrition and reduction in force) of approximately 25% since beginning of January 2022 –RHEA-AIpositive
01/05/23 8:00 AMNasdaq : ALGS clinical triallow floatAligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 – – Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT – SOUTH SANRHEA-AIneutral
12/14/22 4:05 PMNasdaq : ALGS low floatAligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medicalRHEA-AIneutral
12/08/22 8:00 AMNasdaq : ALGS clinical triallow floatAligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART MeetingAligos Therapeutics, Inc. (Nasdaq: ALGS), aRHEA-AIneutral
11/04/22 8:05 AMNasdaq : ALGS clinical triallow floatAligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster presentations also collectively highlight new dataRHEA-AIneutral